No Data
Botuo Biotech 2024 Annual Report
Botuo Biotech 2024 Annual Report Summary
Botuo Biotech\'s 2025 First Quarter Report
Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Last Week's 17% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Wu Shujiang from Botao Bio: Focus on differentiated competition in the in vitro diagnostic Industry POCT subdivision, the commercialization of microfluidic testing products has arrived in its inaugural year | Dialogue with technology innovators.
① "Currently, microfluidic detection products have achieved technical breakthroughs, and customer feedback has been relatively positive." Microfluidic detection products will be the company's new generation of rapid diagnostic products handed over to the market. ② The company focuses on overseas markets, with overseas business accounting for 70%, and the North American and Latin American markets are growing rapidly.
Botao Biology (688767.SH): Deepseek has not been deployed yet.
On March 14, Gelonghui reported that Botuo Biomedical (688767.SH) stated on the interaction platform that the company has not yet deployed Deepseek. The company is closely monitoring the development trends of new technologies such as AI and is actively exploring the application and empowerment of AI and other new technologies in its Business and office.